hearing loss

Pharma

Regeneron ushers in new era with inaugural gene therapy approval

The FDA today approved the company’s Otarmeni, the first gene therapy for a rare genetic form of hearing loss that affects about 50 newborns per year.

Darren Incorvaia Apr 23, 2026 3:22pm

Astellas depreciates FibroGen's Evrenzo, nixes cell therapy deal

Apr 12, 2023 11:02am

Sensorion taps Eveon to deliver gene therapy to inner ear

Jan 31, 2023 10:35am

After 2 CRLs, FDA signs off on Fennec's hearing loss drug

Sep 21, 2022 10:10am

Decibel's hearing loss therapy protects patients in early trial

Jun 28, 2022 9:35am

FDA deals blow to hearing loss treatment for pediatric patients

Nov 29, 2021 11:12am